Ming-Hui Fan, MD
Critical Care Medicine · Boston, MANPI 1063561694
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AstraZeneca at 35.2% of the total. 2021 is the largest year on record at $325, 2.4 times the $136 reported in 2019.
Across 28 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$186
- Grifols USA, LLC$100
- GSK$83
- Regeneron Healthcare Solutions, Inc.$45
- Merck$32
- Boehringer Ingelheim$29
- plus $53 from 3 others
What the payments were for
- Food & beverage$51598%
- Education$132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $186 |
| Grifols USA, LLC | 6 | $100 |
| GSK | 5 | $83 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Merck | 2 | $32 |
| Boehringer Ingelheim | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Genentech USA, Inc. | 1 | $17 |
| Sanofi | 1 | $15 |
How this compares
$528 in reported general payments places this provider in the 65th percentile of 158 critical care medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $550,723 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 30 | $252,777 |
| NucalaMepolizumab | 20 | $231,485 |
| Dupixent PenDupilumab | 50 | $182,013 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 154 | $111,135 |
| Advair HfaFluticasone Propion/Salmeterol | 116 | $43,984 |
| Mycophenolate Mofetil | 75 | $14,386 |
| DuleraMometasone/Formoterol | 31 | $13,464 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $13,297 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,188 |
| Mycophenolic AcidMycophenolate Sodium | 20 | $8,149 |
| Tiotropium Bromide | 16 | $7,972 |
| Wixela InhubFluticasone Propion/Salmeterol | 93 | $7,470 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,202 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $4,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $29 | $550,72339 claims |
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $83 | $363,119217 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $186 | $15,55029 claims |
| MerckDulera | $32 | $13,46431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 158 critical care medicine providers in Massachusetts.
Other critical care medicine in Boston
- Richard ChannickBoston$638K
- Benjamin MedoffBoston$98K
- Jerome CrowleyBoston$38K
- Diana Espinoza BarreraBoston$17K
- Catherine FioreBoston$13K
- Ilana KrummBoston$13K
- John ReichBoston$12K
- Edward BittnerBoston$9K
- Kenneth SheltonBoston$8K
- Leo CeliBoston$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.